CONTACT
+91 80 2808 2808
info@biocon.com
Generics_Banner-biocon
Biocon  /  Products  /  Generics

GENERICS

Generic Formulations and API products are listed below.

GENERIC FORMULATIONS

Sl. No Molecule Name Status
1 Atorvastatin Commercial (U.S.)
2 Aminocaproic Acid Commercial (U.S.)
3 Dapagliflozin Tentative Approval (U.S.)
4 Dasatinib Approved (Chile)
5 Dorzolamide Commercial (U.S.)
6 Dorzolamide Timolol Approved (U.S.)
7 Esomeprazole Commercial (U.S.)
8 Everolimus (RLD Affinitor) Commercial (U.S. & Mexico), Approved (Europe & Saudi Arabia)
9 Famotidine Commercial (U.S.)
10 Fingolimod (Multiple Sclerosis) Approved (U.S., Europe, U.K., & UAE)
11 Labetalol Commercial (U.S.)
12 Lenalidomide Approved (Europe, U.K.)
13 Liothyronine Commercial (U.S.)
14 Mycophenolic Acid Commercial (U.S.) Approved (Singapore)
15 Mycophenolic Sodium Commercial (Israel)
16 Pemetrexed Tentative Approval (U.S.)
17 Posaconazole Commercial (U.S., U.K.) Approved (Europe)
18 Pravastatin Commercial (U.S.)
19 Rosuvastatin Commercial (U.S., Europe, & Singapore)
20 Simvastatin Commercial (U.S.)
21 Tacrolimus Commercial (U.S., Mexico, & Singapore)
22 Teriflunomide Commercial (U.S.)
23 Vigabatrin Approved (U.S.)

API

Cardiology
Sl. No Molecule Name
1 Simvastatin
2 Pravastatin
3 Atorvastatin
4 Rosuvastatin
5 Fluvastatin
6 Dabigatran
7 Sacubitril/Valsartan
8 Apixaban
9 Rivaroxaban
Anti-Diabetics
Sl. No Molecule Name
1 Vildagliptin
2 Linagliptin
3 Sitagliptin (various salts)
4 Dapagliflozin (different solvate forms)
5 Empagliflozin
6 Repaglinide
7 Liraglutide
8 Semaglutide
Immunosuppressants
Sl. No Molecule Name
1 Tacrolimus
2 Sirolimus
3 Everolimus
4 Pimecrolimus
5 Mycophenolate Mofetil (MMF)
6 Mycophenolate Sodium (MPS)
Multiple Sclerosis
Sl. No Molecule Name
1 Glatiramer Acetate
2 Fingolimod
3 Teriflunomide
Anti-Cancer/Oncology
Sl. No Molecule Name
1 Dasatinib
2 Lenalidomide
3 Pazopanib
4 Erdafitinib
Other Key Products
Sl. No Molecule Name
1 Orlistat
2 Mirabegron
3 Posaconazole
4 Micafungin
5 Anidulafungin
6 Brinzolamide
Siddharth Mittal
KEY MANAGEMENT TEAM
PRESS RELEASES
KMS
OUR LEGACY
CORPORATE GOVERNANCE
SUSTAINABILITY
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>